Case Report: A refractory unusual tetrad of overlap syndrome involving rheumatoid arthritis, Sjögren’s syndrome, autoimmune hepatitis, and type 1 renal tubular acidosis, successfully treated with a BLyS/APRIL dual inhibitor

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 18, 2025

Rheumatoid arthritis (RA) and Sjögren's syndrome (SS) are systemic autoimmune conditions. SS frequently occurs associated with RA. In patients RA, those exhibit a higher disease burden, increased activity, more complex comorbidities compared without SS. We report 54-year-old female patient who was previously diagnosed early-stage RA less than 1 year ago. She subsequently confirmed to have Additionally, she developed multiple comorbidities, including hepatitis type renal tubular acidosis. The resisted various treatments, immunosuppressive drugs, disease-modifying antirheumatic anti-inflammatory small-molecule drugs. This evidenced by poor DA28 responses, persistent laboratory abnormalities, ongoing symptoms signs. Finally, responded well Telitacicept, BLyS/APRIL dual inhibitor. Even in the early stage, can high levels of activity may not respond conventional therapies. first inhibitor BLyS/APRIL, has potential provide significant efficacy safety for also overlapping other diseases that do standard treatments. limitations included absence liver biopsy short follow-up period.

Language: Английский

IGJ depletion suppresses proliferation, inflammation, and motility of rheumatoid arthritis fibroblast‐like synoviocytes via targeting NF‐κB pathway

International Journal of Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 27(8)

Published: Aug. 1, 2024

To investigate the impact of IGJ on proliferation, inflammation, and motility rheumatoid arthritis (RA) fibroblast-like synoviocytes elucidate underlying mechanism.

Language: Английский